Industry Trend Analysis - Macroeconomic Difficulties Affecting Hikma In MENA - OCT 2017


BMI View: The combined effects of tough economic conditions and unfavourable currency scenarios in the MENA region continue to weigh Hikma Pharmaceuticals ' performance. As highlighted in recent H117 financial earnings, challenging market conditions in key MENA markets are having a notable impact on total group revenues. Despite this, the region's commercial potential remains significant and strategic advances have given rise to a more positive outlook for the year ahead. New product launches, enhanced partnerships and diversified therapeutic development are key strategies being employed by Hikma in the MENA region.

The Middle East and North Africa (MENA) region will remain central to Hikma Pharmaceuticals' global operations. The Jordan-based drugmaker has a significant presence in the MENA region and has announced a host of plans to boost its presence in key markets to this end, including new product launches and strategic partnerships with other drugmakers. Hikma's key MENA markets include Saudi Arabia, Jordan, Algeria and Egypt.

Challenging Conditions In MENA

Challenging Market Conditions In MENA
Hikma's H1 Revenues (USDmn)
Source: Hikma Pharmaceuticals, BMI

This article is part of our Middle East & Africa coverage. To access this article subscribe now or sign up for free trial